Answers are grounded in this paper and cite their sources.
Framework development reports an esthetic decision-support index for skin barrier screening in cancer clients, suggesting safer skincare risk stratification during active oncology care.
The Kosichenko Oncology Barrier Index (K-OBI) is an authored, evidence-informed, non-diagnostic esthetic screening and decision-support framework for licensed estheticians working with clients during active or recent cancer treatment. It combines a mandatory Safety Stop screen with five weighted domains: oncology treatment context, client-reported skin comfort, visible barrier findings, home-care and external triggers, and esthetic safety modifiers. The provisional 0–100 caution score routes care toward progressively conservative protocols or Safety Hold. K-OBI does not diagnose disease, grade treatment toxicity, recommend cancer treatment, or replace oncology or dermatology evaluation. Its score weights, thresholds, and protocol pathways require prospective validation.
No takes yet. Share an insight, caveat, or question.
Anna Kosichenko (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: